The effect of dual glucose-dependent insulinotropic polypeptide (GIP) and 
glucagon-like peptide-1 (GLP-1) receptor agonist (RA) tirzepatide on gastric 
emptying (GE) was compared to that of GLP-1RAs in non-clinical and clinical 
studies. GE was assessed following acute and chronic treatment with tirzepatide 
in diet-induced obese mice versus semaglutide or long-acting GIP analogue alone. 
Participants [with and without type 2 diabetes (T2DM)] from a phase 1, 4-week 
multiple dose study received tirzepatide, dulaglutide or placebo. GE was 
assessed by acetaminophen absorption. In mice, tirzepatide delayed GE to a 
similar degree to that achieved with semaglutide; however, these acute 
inhibitory effects were abolished after 2 weeks of treatment. GIP analogue alone 
had no effect on GE or on GLP-1's effect on GE. In participants with and without 
T2DM, once-weekly tirzepatide (≥5 and ≥4.5 mg, respectively) delayed GE after a 
single dose. This effect diminished after multiple doses of tirzepatide or 
dulaglutide in healthy participants. In participants with T2DM treated with an 
escalation schedule of tirzepatide 5/5/10/10 or 5/5/10/15 mg, a residual GE 
delay was still observed after multiple doses. These data suggest that 
tirzepatide's activity on GE is comparable to that of selective GLP-1RAs.